Single-nucleotide polymorphism rs670 in the promoter region of the apolipoprotein A-I gene

Abstract

Apolipoprotein A-I (Apo A-I) plays a central role in the function of high-density lipoprotein (HDL). The rs670 single-nucleotide polymorphism (SNP) was identified as a cytosine-to-thymine (C>T) transition in a cytosine-phosphate-guanine site within the promoter region of APOA1. Given its location, studies have hypothesized that this polymorphism may influence APOA1 expression, potentially impacting lipid and carbohydrate metabolism. The aim of this integrative review was to summarize all observational and experimental studies on the rs670 SNP available in the Scopus, ScienceDirect, dbSNP, and LitVar2 databases up to July 2024. In total, 162 articles were identified, of which 28 met the inclusion criteria. Most studies originated from Asia and were published between 2009 and 2023. Of the selected studies, 14 (50%) examined the association of the rs670 SNP with metabolic disorders. Among these, eight (28.57%) reported an association between the polymorphic allele and alterations in lipid profiles, proinflammatory markers, and insulin resistance. The remaining studies explored associations between the polymorphic allele and ischemic events, pharmacological therapies, diet, neurodegenerative diseases, pancreatitis, and breast cancer. The rs670 SNP occurs in more than 20% of the global population. Its position within the promoter region enables it to potentially regulate the APO cluster on chromosome 11. This review underscores the need for further investigation into the impact of this polymorphism on gene expression and its role in the pathogenesis of metabolic syndrome, cardiovascular disease, and cancer.

Keywords

Apolipoprotein A-I / High-density lipoprotein / Lipid metabolism / Singlenucleotide polymorphism

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

References

[1] Feingold KR. Introduction to Lipids and Lipoproteins. Endotext. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305896 [Last accessed on 2024 Jul 08].

[2] Zanoni P,Von Eckardstein A. Inborn errors of apolipoprotein A-I metabolism: Implications for disease, research and development. Curr Opin Lipidol. 2020; 31(2):62-70. doi: 10.1097/MOL.0000000000000667

[3] Zannis VI, Karathanasis SK, Keutmann HT, Goldberger G, Breslow JL. Intracellular and extracellular processing of human apolipoprotein A-I: Secreted apolipoprotein A-I isoprotein 2 is a propeptide. Proc Natl Acad Sci U S A. 1983; 80(9):2574-2578. doi: 10.1073/PNAS.80.9.2574

[4] Baldanzi G, Park B, Lee YJ, et al. APOA1/C3/A4/A5 gene cluster at 11q23.3 and lipid metabolism disorders: From epigenetic mechanisms to clinical practices. Biomedicines. 2024; 12(6):1224. doi: 10.3390/BIOMEDICINES12061224

[5] Seilhamer JJ, Protter AA, Frossard P, Levy-Wilson B. Isolation and DNA sequence of full-length cDNA and of the entire gene for human apolipoprotein AI-discovery of a new genetic polymorphism in the apo AI Gene. DNA. 1984; 3(4):309-317. doi: 10.1089/DNA.1.1984.3.309

[6] Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: Association with hyperalphalipoproteinemia. J Lipid Res. 1990; 31(8):1371-1377. doi: 10.1016/s0022-2275(20)42608-2

[7] Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest. 1992; 89(6):1796-1800. doi: 10.1172/JCI115783

[8] Jeenah M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med. 1990; 7(3):233-241.

[9] RefSNP Report - dbSNP - NCBI - rs670. Available from: https://www.ncbi.nlm.nih.gov/snp/rs670 [Last accessed on 2024 Jul 02].

[10] Wu Y, Yu Y, Zhao T, et al. Interactions of environmental factors and APOA1-APOC3-APOA4-APOA5 gene cluster gene polymorphisms with metabolic syndrome. PLoS One. 2016; 11(1):e0147946. doi: 10.1371/JOURNAL.PONE.0147946

[11] Yang JM, Park JK, Kim SS, Chun W, Lee HJ. Association between apolipoprotein A1 (APOA1) single-nucleotide polymorphisms and schizophrenia in a Korean population. Clin Psychopharmacol Neurosci. 2010; 8(1):45-48.

[12] Smach MA, Edziri H, Charfeddine B, et al. Polymorphism in apoA1 influences high-density lipoprotein cholesterol levels but is not a major risk factor of Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011; 1(1):249-257. doi: 10.1159/000329910

[13] Block R, Corsetti J, Goldenberg I, et al. The common apolipoprotein A-1 polymorphism -75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction. Heart Int. 2009; 4(1):hi.2009.e8. doi: 10.4081/HI.2009.E8

[14] Allot A, Wei CH, Phan L, et al. Tracking genetic variants in the biomedical literature using LitVar 2.0. Nat Genet. 2023; 55(6):901-903. doi: 10.1038/s41588-023-01414-x

[15] Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease. Circ Res. 2019; 124(10):1505. doi: 10.1161/CIRCRESAHA.119.312617

[16] Ruiz-Ramie JJ, Barber JL, Sarzynski MA. Effects of exercise on HDL functionality. Curr Opin Lipidol. 2019; 30(1):16. doi: 10.1097/MOL.0000000000000568

[17] Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics. Biomed Pharmacother. 2022;154:113634. doi: 10.1016/J.BIOPHA.2022.113634

[18] Kluck GEG, Qian AS, Sakarya EH, Quach H, Deng YD, Trigatti BL. Apolipoprotein A1 protects against necrotic core development in atherosclerotic plaques: PDZK1-dependent high-density lipoprotein suppression of necroptosis in macrophages. Arterioscler Thromb Vasc Biol. 2023; 43(1):45-63. doi: 10.1161/ATVBAHA.122.318062

[19] Tang C, Houston BA, Storey C, Leboeuf RC. Both STAT3 activation and cholesterol efflux contribute to the anti-inflammatory effect of apoA-I/ABCA1 interaction in macrophages. J Lipid Res. 2016; 57(5):848-857. doi: 10.1194/JLR.M065797

[20] Wang JL, Gong D, Hu XY, et al. ApoA-1 mimetic peptide ELK-2A2K2E decreases inflammatory factor levels through the ABCA1-JAK2-STAT3-TTP axis in THP-1-derived macrophages. J Cardiovasc Pharmacol. 2018; 72(1):60-67. doi: 10.1097/FJC.0000000000000594

[21] Iqbal AJ, Barrett TJ, Taylor L, et al. Acute exposure to apolipoprotein a1 inhibits macrophage chemotaxis in vitro and monocyte recruitment in vivo. Elife. 2016;5:e15190. doi: 10.7554/ELIFE.15190

[22] Liu D, Ji L, Zhao M, et al. Lysine glycation of apolipoprotein A-I impairs its anti-inflammatory function in type 2 diabetes mellitus. J Mol Cell Cardiol. 2018; 122:47-57. doi: 10.1016/J.YJMCC.2018.08.001

[23] Anantharamaiah GM, Mishra VK, Garber DW, et al. Structural requirements for antioxidative and anti- inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res. 2007; 48(9):1915-1923. doi: 10.1194/JLR.R700010-JLR200

[24] King TW, Cochran BJ, Rye KA. ApoA-I and diabetes. Arterioscler Thromb Vasc Biol. 2023; 43(8):1362-1368. doi: 10.1161/ATVBAHA.123.318267

[25] Tang S, Tabet F, Cochran BJ, et al. Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci Rep. 2019; 9(1):1-9. doi: 10.1038/s41598-018-38014-3

[26] Cochran BJ, Bisoendial RJ, Hou L, et al. Apolipoprotein A-I increases insulin secretion and production from pancreatic β-cells via a G-protein-cAMPPKA-FoxO1- dependent mechanism. Arterioscler Thromb Vasc Biol. 2014; 34(10):2261-2267. doi: 10.1161/ATVBAHA.114.304131/-/DC1

[27] Fung KYY, Ho TWW, Xu Z, et al.Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1. J Lipid Res. 2024; 65(4):100530. doi: 10.1016/J.JLR.2024.100530

[28] Alicia Traughber C, Opoku E, Brubaker G, et al. Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice. J Biol Chem. 2020; 295(24):8252-8261. doi: 10.1074/JBC.RA120.013694

[29] Oberle R, Kührer K, Österreicher T, et al. The HDL particle composition determines its antitumor activity in pancreatic cancer. Life Sci Alliance. 2022; 5(9):e202101317. doi: 10.26508/LSA.202101317

[30] Masimov R, Büyükköroğlu G. HDL-chitosan nanoparticles for siRNA delivery as an SR-B1 receptor targeted system. Comb Chem High Throughput Screen. 2023; 26(14):2541-2553. doi: 10.2174/1386207326666230406124524

[31] Shah A, Rader DJ, Millar JS. The effect of PPAR-α agonism on apolipoprotein metabolism in humans. Atherosclerosis. 2010; 210(1):35-40. doi: 10.1016/j.atherosclerosis.2009.11.010

[32] Khera AV, Millar JS, Ruotolo G, Wang MD, Rader DJ. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015; 36(43):3020-3022. doi: 10.1093/EURHEARTJ/EHV291

[33] Kim MK, Chae YN, Son MH, et al. PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Eur J Pharmacol. 2008; 595(1-3):119-125. doi: 10.1016/J.EJPHAR.2008.07.066

[34] Liang W, Huang L, Whelchel A, et al. Peroxisome proliferator-activated receptor-α (PPARα) regulates wound healing and mitochondrial metabolism in the cornea. Proc Natl Acad Sci U S A. 2023; 120(13):e2217576120. doi: 10.1073/PNAS.2217576120

[35] Wang J, Zhang Y, Zhuo Q, et al. TET1 promotes fatty acid oxidation and inhibits NAFLD progression by hydroxymethylation of PPARα promoter. Nutr Metab (Lond). 2020; 17(1):1-11. doi: 10.1186/S12986-020-00466-8

[36] Chen C, Li H, Song J, et al. Role of apolipoprotein A1 in PPAR signaling pathway for nonalcoholic fatty liver disease. PPAR Res. 2022; 2022(1):4709300. doi: 10.1155/2022/4709300

[37] Mikael LG, Pancer J, Wu Q, Rozen R. Disturbed one-carbon metabolism causing adverse reproductive outcomes in mice is associated with altered expression of apolipoprotein AI and inflammatory mediators PPARα interferon-γ and interleukin-10., J Nutr. 2012; 142(3):411-418. doi: 10.3945/JN.111.151753

[38] Yoshimura Y, Nishii S, Zaima N, Moriyama T, Kawamura Y. Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK-Ay mice. Biochem Biophys Res Commun. 2013; 434(3):486-491. doi: 10.1016/J.BBRC.2013.03.100

[39] Xie X, Zhang T, Zhao S, et al. Effects of n-3 polyunsaturated fatty acids high fat diet intervention on the synthesis of hepatic high-density lipoprotein cholesterol in obesity-insulin resistance rats. Lipids Health Dis. 2016; 15(1):1-7. doi: 10.1186/S12944-016-0250-3/TABLES/3

[40] Tayyeb JZ, Popeijus HE, Mensink RP, Konings MCJM, Mokhtar FBA, Plat J. Short-chain fatty acids (except hexanoic acid) lower NF-kB transactivation, which rescues inflammation-induced decreased apolipoprotein A-I transcription in HepG2 cells. Int J Mol Sci. 2020; 21(14):5088. doi: 10.3390/IJMS21145088

[41] Tayyeb JZ, Popeijus HE, van de Sanden J, Zwaan W, Mensink RP, Plat J. Effects of individual amino acids on PPARα transactivation, mTORC1 activation, ApoA-I transcription and pro-ApoA-I secretion. Int J Mol Sci. 2022; 23(11):6071. doi: 10.3390/IJMS23116071/S1

[42] Volcik KA, Nettleton JA, Ballantyne CM, Boerwinkle E. Peroxisome proliferator-activated receptor α genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2008; 87(6):1926-1931.doi: 10.1093/AJCN/87.6.1926

[43] All Variants in the APOA1 Gene - Global Variome Shared LOVD. Available from: https://databases.lovd.nl/shared/variants/APOA1 [Last accessed on 2024 Jun 26].

[44] RefSNP Report-dbSNP-NCBI-rs28931573. Available from: https://www.ncbi.nlm.nih.gov/snp/rs28931573#clinical_ significance [Last accessed on 2024 Jun 26].

[45] Weisgraber KH, Rall SC, Bersot TP. Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem. 1983; 258(4):2508-2513. doi: 10.1016/S0021-9258(18)32955-7

[46] Halley P, Kadakkuzha BM, Faghihi MA, et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 2014; 6(1):222-230. doi: 10.1016/J.CELREP.2013.12.015

[47] Luis DA de, Izaola O, Primo D, et al. Influencia de la variante rs670 del gen APOA1 en la respuesta HDL sérica a una dieta hipocalórica enriquecida con grasas poliinsaturadas frente a una enriquecida con grasas monoinsaturadas. Nutr Hosp. 2019; 36(6):1288-1295. doi: 10.20960/NH.02390

[48] Hsu MC, Lee KT, Hsiao WC, et al. The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: A 10-year follow-up study. BMC Cancer. 2013; 13(1):1-11. doi: 10.1186/1471-2407-13-330/TABLES/7

[49] Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. The prevalence of metabolic syndrome in various populations. Am J Med Sci. 2007; 333(6):362-371. doi: 10.1097/MAJ.0B013E318065C3A1

[50] Liu Y, Ordovas JM, Gao G, et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: The genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genomics. 2009; 19(2):161-169. doi: 10.1097/FPC.0B013E32831E030E

[51] Mattei J, Demissie S, Tucker KL, Ordovas JM. The APOA1/ C3/A4/A5 cluster and markers of allostatic load in the Boston Puerto Rican Health Study. Nutr Metab Cardiovasc Dis. 2011; 21(11):862-870. doi: 10.1016/J.NUMECD.2010.02.024

[52] Hsu MC, Chang CS, Lee KT, et al. Central obesity in males affected by a dyslipidemia-associated genetic polymorphism on APOA1/C3/A4/A5 gene cluster. Nutr Diabetes. 2013; 3(3):e61. doi: 10.1038/nutd.2013.2

[53] Al-Bustan SA, Al-Serri AE, Annice BG, Alnaqeeb MA, Ebrahim GA. Re-sequencing of the APOAI promoter region and the genetic association of the -75G > A polymorphism with increased cholesterol and low density lipoprotein levels among a sample of the Kuwaiti population. BMC Med Genet. 2013; 14(1):1-11. doi: 10.1186/1471-2350-14-90/TABLES/5

[54] Rudkowska I, Dewailly E, Hegele RA, et al. Gene-diet interactions on plasma lipid levels in the Inuit population. Br J Nutr. 2013; 109(5):953-961. doi: 10.1017/S0007114512002231

[55] Song YY, Gong RR, Zhang Z, et al. Effects of apolipoprotein A1 Gene rs670 and rs5069 polymorphisms on the plasma lipid profiles in healthy adolescents with different body mass index. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014; 36(4):369-376. doi: 10.3881/J.ISSN.1000-503X.2014.04.005

[56] Hosseini-Esfahani F, Mirmiran P, Daneshpour MS, et al. Dietary patterns interact with APOA1/APOC3 polymorphisms to alter the risk of the metabolic syndrome: The Tehran Lipid and Glucose Study. Br J Nutr. 2015; 113(4):644-653. doi: 10.1017/S0007114514003687

[57] Włodarczyk M, Wrzosek M, Nowicka G,Jabłonowska- Lietz B. Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population. Arch Med Sci. 2016; 12(6):1188-1198. doi: 10.5114/AOMS.2016.60870

[58] Feng DW, Ma RL, Guo H, et al. Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang. Genet Mol Res. 2016; 15(2): ???. doi: 10.4238/GMR.15028094

[59] Vorobyeva MA, Azova MM, Gigani OO, Garmash IV, Villevalde SV, Kobalava ZD. Genetic predictors of intensive lipid-lowering therapy efficacy and its anti-inflammatory effects in very high cardiovascular risk patients. Rational Pharmacother Cardiol. 2017; 13(4):525-531. doi: 10.20996/1819-6446-2017-13-4-525-531

[60] Wang X, He J, Guo H, et al. Interactions of six SNPs in APOA1 gene and types of obesity on low HDL-C disease in Xinjiang pastoral area of China. Lipids Health Dis. 2017; 16(1):1-7. doi: 10.1186/S12944-017-0581-8/TABLES/4

[61] Wang Y, Liu F, Li L, Deng S, He Z. The association between apolipoprotein A1-C3-A5 gene cluster promoter polymorphisms and risk of ischemic stroke in the northern Chinese Han population. J Int Med Res. 2017; 45(6):2042-2052. doi: 10.1177/0300060517713517

[62] Hosseini-Esfahani F, Mirmiran P, Daneshpour MS, Mottaghi A, Azizi F. The effect of interactions of single nucleotide polymorphisms of APOA1/APOC3 with food group intakes on the risk of metabolic syndrome. Avicenna J Med Biotechnol. 2017; 9(2):94.

[63] Kovtun OP, Ustyuzhanina MA. Polymorphism of PPARG (P12A), APOA1 (G75A), and APOE (C112A and A158C) genes in children with obesity and arterial hypertension: A case-control study. Curr Pediatr. 2018; 17(4):307-315. doi: 10.15690/VSP.V17I4.1924

[64] Luis DA, Pacheco D, Izaola O, Primo D, Aller R. The association of the rs670 variant of APOA1 gene with insulin resistance and lipid profile in morbid obese patients after a biliopancreatic diversion surgery. Eur Rev Med Pharmacol Sci. 2018; 22(23):8472-8479. doi: 10.26355/EURREV_201812_16547

[65] Wang X, Guo H, Li Y, et al. Interactions among genes involved in reverse cholesterol transport and in the response to environmental factors in dyslipidemia in subjects from the Xinjiang rural area. PLoS One. 2018; 13(5):e0196042. doi: 10.1371/JOURNAL.PONE.0196042

[66] Ściskalska M, Milnerowicz H. Importance of polymorphisms in the gene of paraoxonase-1 (SNP rs662) and apolipoprotein A-I (SNP rs670 and rs5069) in non-smoking and smoking healthy subjects and patients with acute pancreatitis. Genes (Basel). 2022; 13(11):1968. doi: 10.3390/GENES13111968/S1

[67] Supajaree P, Chanprasertyothin S, Shantavasinkul PC, Sritara P, Sirivarasai J. Association between ApoA1 Gene, plasma lipid profile, hsCRP level, and risk of arterial stiffness in thai elderly. Adv Prev Med. 2022; 2022(1):4930033. doi: 10.1155/2022/4930033

[68] Domínguez-Díaz C, Morán-Moguel MC, Navarro- Hernandez RE, Romo-Vázquez R, Mendizabal-Ruiz AP. Association of SNP rs 5069 in APOA1 with benign breast diseases in a Mexican population. Genes (Basel). 2022; 13(5):738. doi: 10.3390/GENES13050738/S1

[69] Casillas FA, Fernández DEM, Valle Y, et al. APOA1 (-75 G>A and 83 C>T) and APOB (2488 C>T) polymorphisms and their association with myocardial infarction, lipids and apolipoproteins in patients with type 2 diabetes mellitus. Arch Med Sci. 2022; 18(6):1438-1445. doi: 10.5114/AOMS/108674

[70] Pérez-Beltrán YE, González-Becerra K, Rivera-Iñiguez I, et al. A nutrigenetic strategy for reducing blood lipids and low-grade inflammation in adults with obesity and overweight. Nutrients. 2023; 15(20):4324. doi: 10.3390/NU15204324/S1

[71] Krishnamurthy HK, Balaguru UM, Pereira M, et al. Influence of genetic polymorphisms on serum biomarkers of cardiac health. Medicine (Baltimore). 2023; 102(23):E33953. doi: 10.1097/MD.0000000000033953